SLXN Announces Phase 2/3 CTA Submission to Germany for SIL204 in KRAS Pancreatic Cancer, Dual-Targeting Trial Planned Q2 2026
Silexion Therapeutics Corp Ordinary Shares · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $4.98
-19% in 7d after detection
Post-detection moves
1h
—
1d
-0.9%
3d
-6.1%
7d
-19%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS